Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
vaccine
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05642195CT.gov Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| h1299 cell lysates (this asset) | National Cancer Institute (NCI) | P1/2 | CCC · 48 |
| Trifluridine | Academic and Community Cancer Research United | P2 | B |
| Palbociclib | Academic and Community Cancer Research United | P2 | B |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P1/2 | B |
| Tipiracil | Academic and Community Cancer Research United | P2 | B |
| Binimetinib | Academic and Community Cancer Research United | P2 | B |
| [68ga]ga-nota-rt4 | RenJi Hospital | P2/3 | CCC |
| [18f]f-resca-rt4 | RenJi Hospital | P2/3 | CCC |
| [18F]F-RESCA-T4 | RenJi Hospital | P2/3 | CCC |
+42 more in the Carcinoma cohort
Other indications for h1299 cell lysates
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Thoracic Cancer | — | P1/2 | CCC · 48 |
| Metastatic Neoplasm | — | P1/2 | CCC · 48 |
| Sarcoma | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. h1299 cell lysates in Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/h1299-cell-lysates-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →